Emerging targets for cancer treatment: S100A9/RAGE

ESMO Open

article

M. Valiente¹  J.M. Sepúlveda²  A. Pérez² 

[1] Brain Metastasis Group;Neuro-Oncology Unit, Hospital Universitario 12 de Octubre;Instituto de Investigación Sanitaria Hospital 12 de Octubre;Servicio de Neurocirugía, Hospital Universitario 12 de Octubre;Departamento de Cirugía, Facultad de Medicina, Universidad Complutense de Madrid

关键词: S100A9;    RAGE;    NF-κB;    JunB;    brain metastasis;    radioresistance;    observational prospective study;    clinical trial with RAGE inhibitor;   

DOI  :  10.1016/j.esmoop.2022.100751

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Developing better treatments that work for the majority of patients with brain metastasis (BM) is highly necessary. Complementarily, avoiding those therapeutic procedures that will not benefit a specific patient is also very relevant. In general, existing therapies for patients with BM could be improved in terms of molecular stratification and therapeutic efficacy. By questioning the benefit of whole brain radiotherapy as provided nowadays and the lack of biomarkers detecting radioresistance, we identified S100A9 and receptor for advanced glycation end-products (RAGE) as a liquid biopsy biomarker and a potential target for a radiosensitizer, respectively. Both of them are being clinically tested as part of the first comprehensive molecular strategy to personalized radiotherapy in BM.

【 授权许可】

CC BY|CC BY-NC-ND